- Screener
- Securities US
- Teva Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd
$13.40
-$0.33
-2.42%
21 Apr 20:00
$12.47
$22.80
52 weeks low/high
Technical analysis
- Trend ClassTurning down
- Trend PowerMedium strength trend
- PatternDescending Wedge
- EMA-20Bearish reversal2025-03-19 the price crossed down the moving average line and getting closer to the MA, which means that the downside trend weakens.
- EMA-50Bearish reversal2025-01-29 the price crossed down the moving average line and demonstrates a downside trend.
- EMA-100Bearish reversal2025-01-29 the price crossed down the moving average line and demonstrates a downside trend.
- StochasticBullishThe stochastic indicator is in the upper part of the neutral territory and it grows. These factors indicate that positive dynamics persists. Last signal: signal line crossed the middle level.
- RSIBearish WeakeningRSI indicator is in overbought territory and it heading south. These factors indicate that perhaps the upside trend is coming to an end. Last signal: entrance to the overbought zone.
- MACDBearish WeakeningOscillator MACD is in the negative territory it's lower than the signal line and grows. These factors mean that the falling trend persists, but the growth rate is declining. Last signal: main and signal line crossing.
- Candle pattern typeDark Clouds CoverIs a candlestick pattern whereby a black candlestick opens above a white candlestick's close and below its midpoint.Considered to be a bearish reversal pattern.Date of signal:
Prices and risks
Price
| Change | Change by industry | Min. | Max. | Volume | |
|---|---|---|---|---|---|
| Yesterday | 3.81% | 4.11% | $13.04 | $13.46 | 28.28M |
| Week | 0.37% | 1.96% | $13.04 | $13.83 | 390.02M |
| Month | -15.23% | 0.15% | $12.47 | $16.28 | 2.59B |
| 3 Months | -37.52% | 5.36% | $12.47 | $22.40 | 9.91B |
| 6 Months | -25.01% | 19.73% | $12.47 | $22.80 | 17.00B |
| Year | 6.11% | 0.64% | $12.47 | $22.80 | 31.74B |
| 3 years | 45.26% | 56.01% | $6.78 | $22.80 | 75.62B |
| 5 years | 39.76% | 76.51% | $6.78 | $22.80 | 117.14B |
| All time | 238.05% | 54.85% | $5.84 | $72.31 | 115.03B |
Volatility
| TEVA | By industry | |
|---|---|---|
| Yesterday | 11.81% | 1.03% |
| Week | 3.31% | 1.76% |
| Month | 15.20% | 9.54% |
| 3 Months | 19.61% | 20.61% |
| 6 Months | 24.96% | 29.79% |
| Year | 47.44% | 41.76% |
| 3 years | 77.38% | 90.20% |
| 5 years | 98.14% | 117.61% |
| All time | — | — |
- Sortino
- 0.06
- Sharpe
- 0.07
- Sterling
- 7.15
- Liquidity index
- 6.34
- Alpha
- 0.00131
- Beta
- 1.09
Fundamental analysis
Indicators for the last quarter and their dynamics for 5 quarters
Ratios
Valuation
Debts
Efficiency
Other ratios
Revenue
Financials
Growth
Assets
Debts
News
About
$15.64B
Capitalization
1.15B
Shares outstanding
Health Care
Sector
Pharmaceuticals
Industry
US8816242098
ISIN
1
Lot size
Mr. Richard D. Francis
CEO
Website
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.